People: Concert Pharmaceuticals Inc (CNCE.OQ)
21 Oct 2020
Mr. Marc A. Becker serves as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer of the Company. Mr. Becker has served as our Chief Financial Officer since January 2018. Prior to joining Concert, Mr. Becker served as the Chief Financial Officer of CRISPR Therapeutics AG, a biotechnology company, from February 2016 to September 2017. From January 2012 to February 2016, Mr. Becker served as the Chief Financial Officer of rEVO Biologics, Inc., a biotechnology company. Prior to rEVO Biologics, Mr. Becker held roles of increasing responsibility at Genzyme Corporation, a biotechnology company subsequently acquired by Sanofi S.A., from 2001 to 2011, culminating in Vice President, Finance. Mr. Becker received a B.S. in Business Administration from the University of Massachusetts and an M.B.A. from Babson College and was licensed as a certified public accountant.
|Total Annual Compensation, USD||393,300|
|Restricted Stock Award, USD||288,515|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||1,205,600|
|Fiscal Year Total, USD||1,887,420|